In a Phase 1 trial (NCT00455416) in patients with early-stage breast cancer, oral EGCG was found to be safe and well tolerated, with evidence of FAS downregulation in tumor tissue and modulation of lipid metabolism (Tuli et al., 2023). The gene discussed is FAS; the disease is neoplasm.